share hit m drug suspension share elan biogen idec plunged monday firm suspended sale new multiple sclerosis drug tysabri patient's death u new york stock exchange share ireland based elan lost 70 u partner biogen idec shed 43 firm took action death central nervous system disease suspected case condition case cited involved use tysabri avonex biogen idec's existing multiple sclerosis drug company said report rare condition progressive multifocal leukoencephalopathy pml patient taking either tysabri avonex alone tysabri approved use u last november widely tipped become world's leading multiple sclerosis treatment company work clinical investigator evaluate tysabri treated patient consult leading expert better understand possible risk pml two firm said statement outcome evaluation used determine possible initiation dosing clinical trial future commercial availability analyst believed product would provide new growth opportunity biogen idec faced increased competition rival avonex elan biggest firm irish stock exchange also expected receive boost new product inquiry elan's account 2002 brought group close bankruptcy firm rebuilding since share price increasing almost four fold last year value company tysabri said ian hunter goodbody stockbroker dublin there's question mark elan finished 18 90 biogen fell 28 63 38 65 share uk pharmaceutical firm phytopharm closed 19 84 151 penny london stock exchange monday said partner set pull deal experimental alzheimer's disease treatment phytopharm said japan's yamanouchi pharmaceutical likely end licensing agreement prompting analyst raise question level future cash reserve